Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET scan may predict heart failure risk after heart attack

NCT ID NCT07684924

Knowledge-focused Sponsor: Ankara University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 28, 2026 · Updated 3 times

Summary

This study explores whether a special PET/MR scan can detect early signs of heart muscle damage after a heart attack. Researchers will scan 25 adults about 10 days after their heart attack and then track their heart function with MRI scans at 3 and 6 months. The goal is to see if the early scan can predict which patients will develop long-term heart remodeling and potential heart failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-FAPI-04 (a radioactive tracer for PET scans)
What this could lead to
If successful, this scan could help doctors identify patients at risk for heart failure after a heart attack, allowing earlier treatment.
What could go wrong
This is a small, early observational study. The scan is experimental and may not reliably predict remodeling or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with acute myocardial infarction prospectively enrolled to undergo hybrid 68Ga-FAPI PET/MR imaging for assessment of myocardial fibroblast activation following infarction.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Diagnosis of acute myocardial infarction according to current guideline criteria. * Successful coronary revascularization when clinically indicated. * Ability to undergo FAPI PET/MR. * Written informed consent. Exclusion Criteria: * Contraindications to MRI (e.g., non-MR-compatible implanted devices, severe claustrophobia). * Pregnancy or breastfeeding. * Severe renal impairment precluding gadolinium administration (if contrast-enhanced MR is performed). * Inability to provide informed consent. * Any condition considered by the investigator to interfere with study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ankara University Faculty of Medicine, Department of Nuclear Medicine

    RECRUITING

    Ankara, 06590, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.